Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 86

Results For "CTO"

4801 News Found

Samsung Epis launches new biotech subsidiary Epis NexLab
Biotech | November 12, 2025

Samsung Epis launches new biotech subsidiary Epis NexLab

The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms


Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
Policy | November 11, 2025

Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices

Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans


CereCore joins oracle partner network to strengthen healthcare IT and EHR services
Digitisation | November 11, 2025

CereCore joins oracle partner network to strengthen healthcare IT and EHR services

The partnership aligns with the launch of Oracle Health’s next-generation electronic health record


Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia
Clinical Trials | November 11, 2025

Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia

The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life


Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial
Clinical Trials | November 10, 2025

Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial

While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage


AstraZeneca delivers double-digit growth
News | November 10, 2025

AstraZeneca delivers double-digit growth

The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy


Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Clinical Trials | November 10, 2025

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026


Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'
Drug Approval | November 10, 2025

Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'

The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases


Novo Nordisk India partners with Emcure to commercialise Poviztra in India
News | November 10, 2025

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy